Environmental and Genetic Risk Factors For Breast Cancer: The Sister Study

乳腺癌的环境和遗传风险因素:姐妹研究

基本信息

项目摘要

We are following a diverse cohort of volunteer women from throughout the US and Puerto Rico between the ages of 35 and 74 who have a sister with breast cancer but did not have breast cancer themselves when they joined the study. At enrollment, data on potential risk factors and current health status were collected using computer assisted telephone interviews and mailed questionnaires. Blood, urine, and environmental samples were collected in a home visit and banked for future use in nested studies of women who develop breast cancer (or other diseases) and a sample of those who don't. The cohort is tracked annually for changes in vital status and major health outcomes. Detailed follow-up questionnaires on health outcomes, environmental and lifestyle exposures, and special topics are completed every 2-3 years. Medical records and tumor tissue (for breast cancer cases) are retrieved for those who develop cancer or other conditions of interest. The cohort was enrolled between 2003 and 2009. Nearly 51,000 women completed all baseline study activities. The response rates for annual updates range from 90-98%. The first Sister Study Biennial follow-up survey was completed in June 2012; responses were obtained from 48,090 women for a response rate of 95%. With the next round of detailed follow-up, which began in January 2012, the study has shifted to triennial administration to reduce participant burden and simplify workflow. Triennial questionnaires have been collected from over 20,000 eligible women to date. More than 1,800 women have reported a diagnosis of breast cancer or DCIS/LCIS; medical records and tumor tissue are being sought for those 6 months post diagnosis. Medical records are also sought for women reporting other cancer types, over 1,600 women to date. In April 2012 the Sister Study Scientific Advisory Board convened to help prioritize a long-term research strategy for addressing questions related to the role of environment and genes in breast cancer. At the Boards suggestion, the Sister Study is assembling a working group to evaluate chemicals of current interest and suitable measurement techniques. Research studies using baseline and follow-up data are exploring risk factors for breast cancer and other health conditions. Recent papers have examined eating patterns and sleep duration, employment and work schedule and telomere length, lifestyle behaviors in black and white women, accuracy and reliability of self-reported weight and height, early life factors in relation to uterine leiomyomata in black women, and early life factors and the risk of rheumatoid arthritis in adulthood. Using data from a case-cohort study involving the first 350 breast cancer cases and a sample of 700 women selected from the cohort, we completed an analysis of telomere length in peripheral blood and breast cancer risk, finding no association in our prospectively collected data. In a study of urinary prostaglandin E2-metabolite (PGE-M) and breast cancer risk in 609 (301 cases and 308 subcohort members) postmenopausal women, several known pro- and anti-inflammatory factors were associated with urinary PGE-M, and post-menopausal breast cancer risk was increased with increasing levels of urinary PGE-M among women who did not regularly use non-steroidal anti-inflammatory drugs (NSAIDs). These results support a role for prostaglandin E2 and inflammation in breast carcinogenesis, which may be modifiable by lifestyle and pharmacological interventions. Analyses are underway for a validation study of over 1,800 participants and their mothers aimed at evaluating how accurately women reported the information on early life collected at baseline, including information on their mothers pregnancy. Preliminary results comparing mothers and daughters responses suggest moderate or better agreement for most of the factors studied. Other studies in progress include early life factors and telomere length in peripheral blood as well as in relation to age at menarche, and analyses examining several factors in relation to breast cancer risk including genetic variants, occupational organic solvent exposure, adiposity, and antibiotic use. A series of analyses are examining DNA global and gene-specific methylation in relation to exposures such as diethylstilbestrol in utero and physical activity throughout the lifetime, as well as in relation to breast cancer risk. Results of several analyses have been presented at national scientific meetings and manuscripts are in preparation for publication. With co-investigators at the University of Washington, the Sister Study completed geocoding participant addresses, allowing attainment of environmental exposure data near participant residences such as current and historical air pollution measurements. A study of exposure to residential air pollution and blood pressure is in progress. Future plans include the development of a comprehensive statistical framework for assessing the health effects of exposure to multi-pollutant mixtures of pollutants, as well as the study of air and other pollutants and the risk of asthma and breast cancer. The Sister Study is conducting breast cancer survivor research with a group from the Division of Cancer Prevention and Control at the Centers for Disease Control and Prevention (CDC), headed by Dr. Mary White, Chief, Epidemiology and Applied Research Branch. This effort is funded in part by the Young Women's Breast Health Awareness and Support of Young Women Diagnosed with Breast Cancer bill, a 2010 congressional bill also known as the EARLY Act. A workshop of experts was held in January 2011 on state-of-the-art breast cancer survivorship research, resulting in recommendations on how the Sister Study can best contribute to this area of research. This collaboration has involved the development and administration of two special surveys. The first, completed in April 2012, covered breast cancer screening practices, family communication about cancer, and the effect of having a sister with breast cancer participants and their families; responses were collected from 20,000 women and data analysis is in progress. The second survey, currently in development, is for women diagnosed with breast cancer and includes topics that are of particular interest to younger women such as body image, work-life balance, relationships and intimacy, and fertility. Together, these surveys will increase our understanding of the impact of cancer in the lives of breast cancer survivors and their families and provide information on survivors quality of life, physical and emotional health, changes in lifestyle and environment, and coordination of cancer treatment and follow-up care that will help identify factors related to healthy living after diagnosis. The Sister Study participates in the National Cancer Institutes Cohort Consortium, a group that facilitates the pooling of data from individual cohort studies to create databases large enough to investigate risk factors for rare cancers. The Sister Study is contributing to Cohort Consortium studies on head and neck, gallbladder and ovarian cancers, allowing it to contribute to research it could not address on its own. The Sister Study is also a member of the International Harmonization Initiative (McGill University, Montreal), an international effort that aims to harmonize data collected across different studies in order to enable collaborative research using large, high-quality databases. A related study known as the Two Sister Study completed enrollment in December 2010. This family-based study on environmental and genetic risk factors for young onset breast cancer builds on the Sister Study by recruiting the participant's sister with breast cancer and parents who were asked to provide a saliva sample for a source of DNA, see Weinberg Z01-ES044005.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Dale P Sandler其他文献

PERCEIVED JOB DISCRIMINATION AND SLEEP HEALTH AMONG WORKING WOMEN: FINDINGS FROM THE SISTER STUDY
职业女性所感受到的工作歧视和睡眠健康:姐妹研究的结果
  • DOI:
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    7
  • 作者:
    Soomi Lee;A. Chang;Dale P Sandler;O. Buxton;Chandra L. Jackson
  • 通讯作者:
    Chandra L. Jackson
Multiple forms of perceived job discrimination and hypertension risk among employed women: Findings from the Sister Study.
就业女性中多种形式的感知工作歧视和高血压风险:姐妹研究的结果。
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    3.5
  • 作者:
    Matthew M Coates;O. Arah;Timothy A. Matthews;Dale P Sandler;Chandra L. Jackson;Jian Li
  • 通讯作者:
    Jian Li
Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group
激素治疗的使用与早发性乳腺癌:绝经前乳腺癌协作组纳入的前瞻性队列的荟萃分析
  • DOI:
    10.1016/s1470-2045(25)00211-6
  • 发表时间:
    2025-07-01
  • 期刊:
  • 影响因子:
    35.900
  • 作者:
    Katie M O’Brien;Melissa G House;Mandy Goldberg;Michael E Jones;Clarice R Weinberg;Amy Berrington de Gonzalez;Kimberly A Bertrand;William J Blot;Jessica Clague DeHart;Fergus J Couch;Montserrat Garcia-Closas;Graham G Giles;Victoria A Kirsh;Cari M Kitahara;Woon-Puay Koh;Hannah Lui Park;Roger L Milne;Julie R Palmer;Alpa V Patel;Thomas E Rohan;Dale P Sandler
  • 通讯作者:
    Dale P Sandler

Dale P Sandler的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Dale P Sandler', 18)}}的其他基金

ENVIRONMENTAL EXPOSURES AND RISK FOR ACUTE LEUKEMIA AND MYELODYSPLASIA IN ADULTS
成人的环境暴露和急性白血病和骨髓增生异常的风险
  • 批准号:
    6106691
  • 财政年份:
  • 资助金额:
    $ 119.83万
  • 项目类别:
Effects Of Dental Treatment During Pregnancy On Childhoo
怀孕期间牙科治疗对儿童的影响
  • 批准号:
    6535077
  • 财政年份:
  • 资助金额:
    $ 119.83万
  • 项目类别:
Cancer Risk In Czech Uranium Miners
捷克铀矿工人的癌症风险
  • 批准号:
    6535069
  • 财政年份:
  • 资助金额:
    $ 119.83万
  • 项目类别:
EXPOSURE TO RADON AND CANCER RISK
接触氡气和癌症风险
  • 批准号:
    6432308
  • 财政年份:
  • 资助金额:
    $ 119.83万
  • 项目类别:
Exposure To Radon And Cancer Risk
接触氡和癌症风险
  • 批准号:
    6837559
  • 财政年份:
  • 资助金额:
    $ 119.83万
  • 项目类别:
Health Effects Of Exposures In Agriculture
农业接触对健康的影响
  • 批准号:
    8336562
  • 财政年份:
  • 资助金额:
    $ 119.83万
  • 项目类别:
Exposure To Radon And Cancer Risk
接触氡和癌症风险
  • 批准号:
    7007179
  • 财政年份:
  • 资助金额:
    $ 119.83万
  • 项目类别:
Risk Factors For Attention Deficit/hyperactivity Disorde
注意力缺陷/多动症的危险因素
  • 批准号:
    7007399
  • 财政年份:
  • 资助金额:
    $ 119.83万
  • 项目类别:
Exposure To Radon And Cancer Risk
接触氡和癌症风险
  • 批准号:
    7168888
  • 财政年份:
  • 资助金额:
    $ 119.83万
  • 项目类别:
Gulf Longitudinal Follow-up (GuLF) Study
海湾纵向随访(GuLF)研究
  • 批准号:
    8929812
  • 财政年份:
  • 资助金额:
    $ 119.83万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 119.83万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 119.83万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 119.83万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 119.83万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 119.83万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 119.83万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 119.83万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 119.83万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 119.83万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 119.83万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了